Drug
Camonsertib clinical trials
Also written RP-3500.
Keep track of what changes. Save the camonsertib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2021 (3); 1 more planned to start later
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2021 | 3 |
| 2022 | 1 |
| 2023 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 4
Hoffmann-La Roche (2) · Canadian Cancer Trials Group (2) · Memorial Sloan Kettering Cancer Center (1) · Debiopharm International SA (1) · National Cancer Institute (NCI) (1) · Repare Therapeutics (1)
Often tested with
Tested in the same studies.
Gemcitabine (3) · Atezolizumab (2) · Ipatasertib (2) · Sacituzumab govitecan (2) · Entrectinib (1) · Alectinib (1) · Ado-Trastuzumab Emtansine (1) · Inavolisib (1)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Studies
Open first, then newest update. How each study uses camonsertib is read from its arms, and is right about nine times in ten.
Testing it · 8
- Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid TumorsRecruitingPhase 1Debiopharm International SANCT04855656Written as RP-3500
- Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell CarcinomaRecruitingPhase 1National Cancer Institute (NCI)NCT07156227Written as Camonsertib
- Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast CancerRecruitingPhase 2Canadian Cancer Trials GroupNCT05601440Written as RP-3500
- Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform StudyActive, not recruitingPhase 2Hoffmann-La RocheNCT04589845Written as Camonsertib
- A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)TerminatedPhase 1/2Hoffmann-La RocheNCT03337698Written as Camonsertib
- RP-6306 in Patients With Advanced CancerCompletedPhase 2Canadian Cancer Trials GroupNCT05605509Written as RP-3500
- A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor CancerActive, not recruitingPhase 1/2Memorial Sloan Kettering Cancer CenterNCT05566574Written as RP-3500
- Study of RP-3500 (Camonsertib) With Niraparib or Olaparib in Advanced Solid TumorsTerminatedPhase 1/2Repare TherapeuticsNCT04972110Written as RP-3500 (camonsertib)
Given in every arm · 2 — camonsertib is usual care beside what is tested
- Study of RP-3500, Camonsertib, in Advanced Solid TumorsCompletedPhase 1/2Repare TherapeuticsNCT04497116Written as RP-3500 (camonsertib)
- RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic LeukemiaTerminatedPhase 1/2University of UtahNCT05405309Written as RP-3500
Codes
What other systems call camonsertib · ClinicalTrials.gg INT017839
- UNII (FDA) S1Z7Y5G56TCAMONSERTIBOne source FDA
- NCI Thesaurus C174206CamonsertibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | S1Z7Y5G56T | CAMONSERTIB | One source FDA |
| NCI Thesaurus | C174206 | Camonsertib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.